Risk of symptomatic COVID-19 due to aircraft transmission: a retrospective cohort study of contact-traced flights during England's containment phase.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
05 2021
Historique:
revised: 09 01 2021
received: 01 12 2020
accepted: 12 01 2021
pubmed: 3 3 2021
medline: 6 5 2021
entrez: 2 3 2021
Statut: ppublish

Résumé

Knowledge gaps remain regarding SARS-CoV-2 transmission on flights. We conducted a retrospective cohort study to estimate risk of acquiring symptomatic SARS-CoV-2 on aircraft, to inform contact tracing and infection control efforts. We identified co-passengers of infectious passengers on 18 England-bound flights from European cities up to 12/03/2020, using manifests received for contact tracing. Infectious passengers were laboratory-confirmed cases with symptom onset from 7 days before to 2 days after the flight. Possible aircraft-acquired cases were laboratory-confirmed with onset 3-14 days post-flight with no known non-flight exposure. Manifests was merged with the national case management dataset (identifying cases, onset dates, contact tracing status) and the national COVID-19 linelist. Contact tracing notes were reviewed to identify non-flight exposures. We calculated attack rates (ARs) among all co-passengers and within subgroups, including by distance from infectious cases and number of infectious cases on-board. There were 55 infectious passengers and 2313 co-passengers, including 2221 flight-only contacts. Five possible aircraft-acquired cases were identified; ARs of 0.2% (95%CI 0.1-0.5) among all flight-only contacts and 3.8% (95%CI 1.3-10.6) among contact-traced flight-only contacts sat within a two-seat radius. The AR among 92 co-travellers with known non-flight exposure to infectious cases was 13.0% (95%CI 7.6%-21.4%). There were insufficient numbers to assess differences between subgroups. We conclude that risk of symptomatic COVID-19 due to transmission on short to medium-haul flights is low, and recommend prioritising contact-tracing of close contacts and co-travellers where resources are limited. Further research on risk on aircraft is encouraged.

Sections du résumé

BACKGROUND
Knowledge gaps remain regarding SARS-CoV-2 transmission on flights. We conducted a retrospective cohort study to estimate risk of acquiring symptomatic SARS-CoV-2 on aircraft, to inform contact tracing and infection control efforts.
METHODS
We identified co-passengers of infectious passengers on 18 England-bound flights from European cities up to 12/03/2020, using manifests received for contact tracing. Infectious passengers were laboratory-confirmed cases with symptom onset from 7 days before to 2 days after the flight. Possible aircraft-acquired cases were laboratory-confirmed with onset 3-14 days post-flight with no known non-flight exposure. Manifests was merged with the national case management dataset (identifying cases, onset dates, contact tracing status) and the national COVID-19 linelist. Contact tracing notes were reviewed to identify non-flight exposures. We calculated attack rates (ARs) among all co-passengers and within subgroups, including by distance from infectious cases and number of infectious cases on-board.
RESULTS
There were 55 infectious passengers and 2313 co-passengers, including 2221 flight-only contacts. Five possible aircraft-acquired cases were identified; ARs of 0.2% (95%CI 0.1-0.5) among all flight-only contacts and 3.8% (95%CI 1.3-10.6) among contact-traced flight-only contacts sat within a two-seat radius. The AR among 92 co-travellers with known non-flight exposure to infectious cases was 13.0% (95%CI 7.6%-21.4%). There were insufficient numbers to assess differences between subgroups.
CONCLUSION
We conclude that risk of symptomatic COVID-19 due to transmission on short to medium-haul flights is low, and recommend prioritising contact-tracing of close contacts and co-travellers where resources are limited. Further research on risk on aircraft is encouraged.

Identifiants

pubmed: 33650201
doi: 10.1111/irv.12846
pmc: PMC8013760
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

336-344

Informations de copyright

© 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Références

Influenza Other Respir Viruses. 2021 May;15(3):336-344
pubmed: 33650201
J Med Virol. 2020 Nov;92(11):2543-2550
pubmed: 32470164
Emerg Infect Dis. 2020 Nov;26(11):2713-2716
pubmed: 32946370
Ann Glob Health. 2016 Sep - Oct;82(5):819-823
pubmed: 28283135
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3623-3627
pubmed: 29555754
CMAJ. 2020 Apr 14;192(15):E410
pubmed: 32392504
Travel Med Infect Dis. 2020 May - Jun;35:101643
pubmed: 32247016
Commun Dis Intell (2018). 2020 Jul 2;44:
pubmed: 32615916
Emerg Infect Dis. 2020 Nov;26(11):2617-2624
pubmed: 32946369

Auteurs

Paula Bianca Blomquist (PB)

UK Field Epidemiology Training Programme, Public Health England, London, United Kingdom.
North West Field Services, National Infection Service, Public Health England, Liverpool, United Kingdom.

Hikaru Bolt (H)

South East and London Field Services, National Infection Service, Public Health England, London, United Kingdom.

Simon Packer (S)

South West Field Services, National Infection Service, Public Health England, Bristol, United Kingdom.

Ulf Schaefer (U)

Core Bioinformatics Group, Data and Analytical Sciences, National Infection Service, Public Health England, London, United Kingdom.

Steven Platt (S)

National Infection Service, Public Health England, London, United Kingdom.

Gavin Dabrera (G)

National Infection Service, Public Health England, London, United Kingdom.

Maya Gobin (M)

South West Field Services, National Infection Service, Public Health England, Bristol, United Kingdom.

Isabel Oliver (I)

National Infection Service, Public Health England, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH